Is Moderna Stock a Good Investment?

Moderna Investment Advice

MRNA

To provide specific investment advice or recommendations on Moderna stock, we recommend investors consider the following general factors when evaluating Moderna. This will help you to make an informed decision on whether to include Moderna in one of your diversified portfolios:

Examine Moderna's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Moderna's leadership team and their track record. Good management can help Moderna navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Biotechnology space and any emerging trends that could impact Moderna's business and its evolving consumer preferences.
Compare Moderna's performance and market position to its competitors. Analyze how Moderna is positioned in terms of product offerings, innovation, and market share.
Check if Moderna pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Moderna's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Moderna stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Moderna is a good investment.

Sell

Buy

Strong Sell

Our trade recommendations module can be used to complement Moderna advice provided by average analyst sentiment. It analyzes the firm's potential to grow using fundamental, technical, data market data available at the time. To make sure Moderna is not overpriced, please verify all Moderna fundamentals, including its price to sales, cash per share, and the relationship between the number of shares shorted and ebitda . Given that Moderna has a number of shares shorted of 40.6 M, we recommend you to check Moderna market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your last-minute risk tolerance and investing horizon.

Market Performance	Very Weak	Details
Volatility	Not too volatile	Details
Hype Condition	Stale	Details
Current Valuation	Overvalued	Details
Odds Of Distress	Low	Details
Economic Sensitivity	Follows the market closely	Details
Investor Sentiment	Alarmed	Details
Analyst Consensus	Not Available	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Unavailable	Details

Examine Moderna Stock

Researching Moderna's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 74.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.26. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moderna recorded a loss per share of 9.28. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 3rd of August 2017.

To determine if Moderna is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Moderna's research are outlined below:

	Moderna generated a negative expected return over the last 90 days
	Moderna has high historical volatility and very poor performance
	The company reported the previous year's revenue of 3.24 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.77 B).
	Moderna currently holds about 8.35 B in cash with (3 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73.
	Roughly 74.0% of the company shares are owned by institutional investors

Moderna uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Moderna. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Moderna's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	22nd of February 2024 Upcoming Quarterly Report	View
	2nd of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	22nd of February 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

Moderna's market capitalization trends

The company currently falls under 'Large-Cap' category with a current market capitalization of 13.08 B.

Moderna's profitablity analysis

The company has Profit Margin (PM) of (1.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.29) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.29.

Determining Moderna's profitability involves analyzing its financial statements and using various financial metrics to determine if Moderna is a good buy. For example, gross profit margin measures Moderna's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Moderna's profitability and make more informed investment decisions.

Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.

Basic technical analysis of Moderna Stock

As of the 26th of February, Moderna secures the Standard Deviation of 5.0, mean deviation of 3.7, and Risk Adjusted Performance of (0.03). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Moderna, as well as the relationship between them.

Moderna's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Moderna insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Hoge Stephen over three weeks ago Acquisition by Hoge Stephen of 523 shares of Moderna subject to Rule 16b-3
		James Mock over a month ago Disposition of 1453 shares by James Mock of Moderna subject to Rule 16b-3
		Noubar Afeyan over six months ago Disposition of 2100 shares by Noubar Afeyan of Moderna at 121.5699 subject to Rule 16b-3
		Noubar Afeyan over six months ago Disposition of 7996 shares by Noubar Afeyan of Moderna at 122.0689 subject to Rule 16b-3
		James Mock over six months ago Disposition of 705 shares by James Mock of Moderna at 101.9281 subject to Rule 16b-3

Moderna's Outstanding Corporate Bonds

Moderna issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Moderna uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Moderna bonds can be classified according to their maturity, which is the date when Moderna has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	MPLX LP 4125 Corp Bond US55336VAK61	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	MGM Resorts International Corp Bond US552953CD18	View

View All Moderna Corporate Bonds

Understand Moderna's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Moderna's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	(0.03)
	Market Risk Adjusted Performance	(0.30)
	Mean Deviation	3.7
	Coefficient Of Variation	(1,926)
	Standard Deviation	5.0
	Variance	25.05
	Information Ratio	(0.05)
	Jensen Alpha	(0.27)
	Total Risk Alpha	(0.30)
	Treynor Ratio	(0.31)
	Maximum Drawdown	28.46
	Value At Risk	(9.17)
	Potential Upside	8.37
	Skewness	(0.37)
	Kurtosis	1.44

	Risk Adjusted Performance	(0.03)
	Market Risk Adjusted Performance	(0.30)
	Mean Deviation	3.7
	Coefficient Of Variation	(1,926)
	Standard Deviation	5.0
	Variance	25.05
	Information Ratio	(0.05)
	Jensen Alpha	(0.27)
	Total Risk Alpha	(0.30)
	Treynor Ratio	(0.31)
	Maximum Drawdown	28.46
	Value At Risk	(9.17)
	Potential Upside	8.37
	Skewness	(0.37)
	Kurtosis	1.44

Consider Moderna's intraday indicators

Moderna intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Moderna stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	813773.0
	Daily Balance Of Power	(0.24)
	Rate Of Daily Change	0.98
	Day Median Price	34.21
	Day Typical Price	33.9
	Price Action Indicator	(1.24)
	Period Momentum Indicator	(0.62)
	Relative Strength Index	35.82

Moderna time-series forecasting models is one of many Moderna's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Moderna's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Moderna Stock media impact

Far too much social signal, news, headlines, and media speculation about Moderna that are available to investors today. That information is available publicly through Moderna media outlets and privately through word of mouth or via Moderna internal channels. However, regardless of the origin, that massive amount of Moderna data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Moderna news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Moderna relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Moderna's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Moderna alpha.

Moderna Corporate Management

Shannon Klinger	Chief Secretary	Profile
Brad Miller	Chief Officer	Profile
Melanie MBA	Chief Officer	Profile
James Mock	Chief Officer	Profile
Stephane Bancel	CEO Director	Profile
John Reynders	Chief Officer	Profile
Ruchi Jain	Principal Scientist	Profile

When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock: